Skip to main content

Table 5 Background factors in patients with lean NAFLD stratified by fibrosis stage

From: Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

 

Fibrosis stage 0–2 (n = 132)

Fibrosis stage 3–4 (n = 38)

P value

Age

49 (18–79)

67 (28–85)

 < 0.01

Sex, male (%)

64.4

50.0

0.132

BMI (kg/m2)

23.1 (18.8–24.8)

23.3 (18.1–24.9)

0.388

History of liver cancer (%)

4.6

23.7

 < 0.01

History of non-liver malignancy (%)

6.9

18.4

0.054

Type 2 diabetes mellitus (%)

16.2

50.0

 < 0.01

Dyslipidemia (%)

25.8

36.8

0.220

Hypertension (%)

29.5

39.5

0.323

Hyperuricemia (%)

2.3

5.3

0.311

Smoking (%)

22.8

19.4

0.821

Albumin (g/dL)

4.1 (2.8–5.4)

4.1 (2.8–4.9)

0.083

Aspartate aminotransferase (IU/L)

36 (12–312)

46 (17–139)

 < 0.01

Alanine aminotransferase (IU/L)

56 (13–458)

41 (17–280)

0.311

Gamma-glutamyl transpeptidase (IU/L)

79 (11–786)

63 (17–285)

0.184

Hemoglobin (g/dL)

14.7 (10.1–17.5)

13.9 (6.5–16.4)

 < 0.01

Platelet count (× 104/μL)

23.8 (9.8–47.1)

15.5 (4.0–32.8)

 < 0.01

Triglyceride (mg/dL)

131 (31–1088)

125 (36–610)

0.287

Total cholesterol (mg/dL)

202 (101–290)

178 (101–280)

 < 0.01

High-density lipoprotein cholesterol (mg/dL)

47 (23–85)

45 (22–85)

0.589

Low-density lipoprotein cholesterol (mg/dL)

117 (27–218)

95 (29–185)

 < 0.01

Fasting blood sugar (mg/dL)

98 (70–159)

118 (76–237)

 < 0.01

Glycated hemoglobin (%)

5.7 (4.7–9.3)

6.1 (4.4–10.8)

0.022

Ferritin (ng/mL)

180 (10–697)

231 (10–1472)

0.083

NAFLD fibrosis score

− 2.862 (− 7.060 to 1.566)

− 0.193 (− 4.723 to 3.095)

 < 0.01

Genetic variation

   

 Cases tested, (n)

83

27

 

  PNPLA3 rs738409, GG (%)

34.9

63.0

0.014

  TM6SF2 rs58542926, non CC (%)

25.3

29.6

0.802

  HSD17B13 rs6834314, non AA (%)

54.2

63.0

0.506

Histopathological findings

   

 Cases tested, (n)

132

37

 

  Steatosis 3 (%)

18.9

18.9

1

  Ballooning 2 (%)

15.9

45.9

 < 0.01

  Lobular inflammation 2–3 (%)

18.9

40.5

 < 0.01

  NAFLD activity score 5–8 (%)

31.1

48.6

0.053

  1. Data are number of patients or median (range) values
  2. P value by Mann–Whitney U test for continuous parameters and Fisher’s exact test for categorical parameters
  3. aSteatosis 3, steatosis of ≥ 66% of hepatocytes, bBallooning 2, hepatocyte ballooning of many cells, cLobular inflammation 2–3, ≥ 2 foci per 200 × field
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us